logo-loader
viewAstraZeneca

AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism

diabetes on a dial
Type-1 diabetes is a chronic disease where the pancreas produces little or no insulin

AstraZeneca PLC (LON:AZN) has won regulatory approval for a breakthrough diabetes drug with its new product Forxiga becoming the first oral treatment for the type-1 form of the disease in Europe.

It will be used as an “adjunct” to insulin for people whose glucose levels are not adequately controlled with the hormone alone.

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism.

It is estimated that there are just over 300,000 UK sufferers of type-1 diabetes, a chronic disease that means pancreas produces little or no insulin.

The condition is caused by an autoimmune reaction that destroys the beta cells in the pancreas, which make insulin.

Quick facts: AstraZeneca

Price: 7229 GBX

LSE:AZN
Market: LSE
Market Cap: £94.84 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PCF Bank's Scott Maybury reports on strong lending growth and increased...

PCF Group Plc's (LON:PCF) Scott Maybury speaks to Proactive London's Andrew Scott after the specialist lender posted record numbers in its latest year. Loans outstanding rose 55% to £339mln with profits for the twelve months to September climbing by 54% to £8mln. Maybury says targets for a...

7 hours, 21 minutes ago

2 min read